Eli Lilly (LLY)
(Delayed Data from NYSE)
$797.45 USD
+21.07 (2.71%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $798.17 +0.72 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$797.45 USD
+21.07 (2.71%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $798.17 +0.72 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Zacks Earnings Trends Highlights: Pfizer, Eli Lilly, General Motors and Tesla
by Zacks Equity Research
Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.
Earnings Estimates Come Under Pressure
by Sheraz Mian
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.
Earnings Estimates Come Under Pressure
by Sheraz Mian
While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss
by Zacks Equity Research
Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
by Sweta Killa
Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.
Company News for Nov 03, 2023
by Zacks Equity Research
Companies In The Article: LLY, SBUX, SHOP, CYBR
Eli Lilly (LLY) Q3 Earnings & Sales Top, EPS View Cut, Stock Up
by Zacks Equity Research
Eli Lilly (LLY) beats third-quarter estimates for earnings as well as sales. It cut its earnings guidance for 2023 on charges related to acquisitions and collaboration deals.
Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Curious about Lilly (LLY) Q3 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Lilly (LLY) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Incyte (INCY) Beats on Q3 Earnings, Misses Revenue Estimates
by Zacks Equity Research
Incyte's (INCY) third-quarter 2023 earnings beat estimates, while revenues miss the same. The company tightens Jakafi net product revenue guidance for 2023.
5 Hot Earnings Charts
by Tracey Ryniec
These 5 companies have red hot charts and they have outstanding earnings surprise histories.
Pfizer (PFE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pfizer (PFE) delivered earnings and revenue surprises of 46.88% and 3.93%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Pre-Markets in Green to Start a Crucial Week of Events
by Zacks Equity Research
Pre-Markets in Green to Start a Crucial Week of Events.
Busy Week for Earnings, Fed, Reports; MCD, ON Beat in Q3
by Mark Vickery
Mid-October near-term highs have given way to lower trading levels for the most part in the past couple weeks.
Pharma Stock Roundup: SNY, MRK, NVS Report Q3 Earnings, FDA Okays PFE, LLY Products
by Kinjel Shah
Merck (MRK), Sanofi (SNY) and Novartis (NVS) report third-quarter results. FDA approves Pfizer's (PFE) Penbraya and Eli Lilly's (LLY) Omvoh
Earnings Preview: Eli Lilly (LLY) Q3 Earnings Expected to Decline
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 9.79% and 3.80%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.
Eli Lilly (LLY) Stock Moves -1.01%: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed at $586.46 in the latest trading session, marking a -1.01% move from the prior day.
Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QUS
Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for GSEW
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS